
Pfizer announces strong Phase III results for atopic dermatitis drug
pharmafile | July 14, 2016 | News story | Research and Development |ย ย Pfizer, anacor, atopic dermatitis, crisaborole, eczemaย
Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild to moderate atopic dermatitis.
The company acquired the investigational compound as part of their $5.2 billion takeover of Anacor Pharmaceuticals in May. Crisaborole is a differentiated non-steroidal topical PED4 inhibitor with anti-inflammatory properties. At the time of the takeover, Pfizer indicated its peak sales could have the potential to reach or exceed $2 billion.
In these Phase III trials, the results of which were published in the Journal of the American Academy of Dermatology, the drug achieved statistically significant results on primary and secondary endpoints, including patientโs investigator static global assessment (ISGA) score, and changes in baseline of dermatitis rating.
Amy Paller, professor of paediatrics at Northwestern University, says: โAtopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults. There have been no new therapies approved in the US for people with atopic dermatitis in the last 15 years. The results seen in these pivotal Phase III studies demonstrated that crisaborole, if approved, could be a meaningful treatment option for patients with mild to moderate atopic dermatitis.โ
Sean Murray
Related Content

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …






